Physician profile
Eric H M Yang
NPI 1205028644
$36,614.61
in general payments reported to CMS, 2019-2025
21 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.36 · 2021: $184 · 2022: $5,515 · 2023: $7,291 · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Honoraria: $5,000 · Food and Beverage: $2,681 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Travel and Lodging: $1,441 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $496 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,737.50 |
| Honoraria | $5,000.00 |
| Food and Beverage | $2,680.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Travel and Lodging | $1,441.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $496.03 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $26,308.70 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Evoque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,554.41 | 2024-2025 | Lifevest |
| Abbott Laboratories | $926.01 | 2023-2025 | Triclip, Dragonfly Opstar, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $712.99 | 2023-2024 | |
| Medtronic, INC. | $273.98 | 2023 | Corevalve Evolut R, Intellis Adaptivestim |
| Abiomed | $254.02 | 2023-2025 | Impella |
| Philips North America LLC | $137.33 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Biotronik Nro, INC. | $131.96 | 2023 | Biotronik |
| Kestra Medical Technology Services, INC. | $62.50 | 2023 | Assure Wcd |
| Cleerly, INC. | $56.01 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Boston Scientific Corporation | $51.68 | 2024 | Wavewriter Alpha Prime 16 |
| Atricure, INC. | $37.35 | 2025 | Atriclip Laa Exclusion System |
| Novo Nordisk INC | $32.27 | 2024 | Ozempic |
| Lantheus Medical Imaging, INC. | $25.70 | 2024 | |
| Amgen INC. | $21.34 | 2023 | Repatha |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $14.26 | 2019 | |
| Melinta Therapeutics, LLC | $14.10 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.